IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.259
NA - Nord America 13.797
AS - Asia 6.325
SA - Sud America 2.125
Continente sconosciuto - Info sul continente non disponibili 312
AF - Africa 198
OC - Oceania 13
Totale 37.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.416
RU - Federazione Russa 7.039
SG - Singapore 2.712
BR - Brasile 1.829
CN - Cina 1.818
IE - Irlanda 1.625
SE - Svezia 1.613
IT - Italia 891
HK - Hong Kong 682
DE - Germania 579
PL - Polonia 529
UA - Ucraina 507
FR - Francia 504
GB - Regno Unito 337
FI - Finlandia 294
VN - Vietnam 292
IN - India 194
CA - Canada 157
AR - Argentina 109
BD - Bangladesh 100
BE - Belgio 74
MX - Messico 71
IQ - Iraq 63
AT - Austria 61
ZA - Sudafrica 60
JP - Giappone 58
TR - Turchia 57
CO - Colombia 50
ES - Italia 45
ID - Indonesia 45
EC - Ecuador 42
UZ - Uzbekistan 35
NL - Olanda 34
VE - Venezuela 34
MA - Marocco 31
PK - Pakistan 31
IL - Israele 26
PH - Filippine 25
CR - Costa Rica 23
JM - Giamaica 22
AE - Emirati Arabi Uniti 19
KE - Kenya 19
SA - Arabia Saudita 18
SC - Seychelles 18
TN - Tunisia 18
NP - Nepal 17
AL - Albania 16
CZ - Repubblica Ceca 16
HN - Honduras 16
PY - Paraguay 16
AZ - Azerbaigian 14
CL - Cile 14
NI - Nicaragua 14
DO - Repubblica Dominicana 13
JO - Giordania 13
MY - Malesia 13
DZ - Algeria 12
EG - Egitto 12
KG - Kirghizistan 12
LT - Lituania 12
CW - ???statistics.table.value.countryCode.CW??? 11
PE - Perù 11
SV - El Salvador 11
TT - Trinidad e Tobago 11
KZ - Kazakistan 10
OM - Oman 10
BO - Bolivia 9
GP - Guadalupe 9
GT - Guatemala 9
IR - Iran 9
PR - Porto Rico 9
CH - Svizzera 8
EU - Europa 8
PS - Palestinian Territory 8
UY - Uruguay 8
AU - Australia 7
BG - Bulgaria 7
HR - Croazia 7
LB - Libano 7
LV - Lettonia 7
RO - Romania 7
SK - Slovacchia (Repubblica Slovacca) 7
TH - Thailandia 7
CI - Costa d'Avorio 6
RS - Serbia 6
AO - Angola 5
GE - Georgia 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
PA - Panama 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
ET - Etiopia 4
NO - Norvegia 4
BB - Barbados 3
BN - Brunei Darussalam 3
EE - Estonia 3
GA - Gabon 3
Totale 36.687
Salva come PNG Salva come JPEG
Città #
Moscow 2.045
Ashburn 1.856
Dublin 1.619
Singapore 1.509
Chandler 1.366
Dallas 1.105
Jacksonville 1.015
Nyköping 847
San Jose 782
Hong Kong 680
Beijing 640
Warsaw 510
Council Bluffs 455
New York 359
The Dalles 326
Los Angeles 279
Ann Arbor 276
Princeton 272
Medford 258
Dearborn 250
Cambridge 239
Lauterbourg 229
Des Moines 215
Messina 174
Boardman 167
São Paulo 150
Buffalo 139
Tianjin 96
Santa Clara 94
Munich 93
Woodbridge 88
Jinan 83
Frankfurt am Main 80
Ho Chi Minh City 76
Brussels 71
Lancaster 71
Hanoi 70
Pune 61
Wilmington 60
Orem 58
Brooklyn 57
Rio de Janeiro 57
Phoenix 56
Shenyang 55
Redondo Beach 54
San Mateo 54
Belo Horizonte 52
Tokyo 49
Guangzhou 48
Vienna 47
Chicago 46
Dong Ket 46
Houston 46
Montreal 44
Atlanta 42
Nanjing 42
Chennai 41
San Francisco 39
Rome 37
Columbus 36
Johannesburg 36
Hebei 34
London 34
Zhengzhou 33
Brasília 32
Tashkent 32
Seattle 31
Turku 30
Nuremberg 29
Milan 28
Shenzhen 28
Denver 27
Manchester 27
Porto Alegre 27
Shanghai 27
Stockholm 27
Helsinki 26
Haikou 25
Jakarta 25
Boston 24
Campinas 23
Hangzhou 23
Toronto 23
Baghdad 22
Mexico City 22
Mumbai 22
Nanchang 21
Washington 21
Changsha 20
Goiânia 20
Leawood 19
Ningbo 19
Quito 19
Taizhou 19
Curitiba 18
Jiaxing 18
Nairobi 18
San José 18
Amsterdam 17
Düsseldorf 17
Totale 20.692
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 434
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 258
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 252
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 251
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 249
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 249
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 242
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 231
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 230
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 227
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 224
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 223
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 222
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 215
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 214
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 213
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 207
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 205
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 204
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 203
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 201
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 198
[Serum levels of copper and zinc in patients with lung cancer] 195
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 195
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors 194
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 193
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 193
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 192
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 192
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 192
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 192
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 191
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 191
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 190
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 188
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 187
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 187
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 186
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 186
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 185
Biological parameters in breast cancer. 185
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 185
The treatment of peritoneal carcinomatosis in elderly patients. 183
Unusual relapse of hepatocellular carcinoma 182
Breast. La terapia primaria: stato dell'arte 181
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 180
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 180
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 179
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 179
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 179
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 179
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 178
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 178
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 177
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 177
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 177
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 177
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 176
Extended RAS mutation testing on wild-type KRAS exon 2 metastatic colorectal cancer. 176
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 175
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 175
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 175
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 174
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 173
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 173
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 173
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 171
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 171
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 170
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 170
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 170
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 170
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 169
Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy 167
Peritoneal carcinomatosis of colorectal origin. 167
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 167
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 166
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 166
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 166
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries 166
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 165
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. 164
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 164
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 164
Liquid biopsy tracking of lung tumor evolutions over time 164
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 163
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 163
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 162
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 162
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 161
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 161
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study 159
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 159
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 158
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 158
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 157
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 156
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 156
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 155
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 154
Totale 18.768
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.434 0 0 0 0 58 16 106 63 15 320 265 591
2022/20235.013 389 493 216 417 379 512 80 325 1.984 19 141 58
2023/20241.301 101 186 69 108 71 498 66 56 5 46 11 84
2024/20255.070 66 47 92 313 258 168 106 1.119 1.341 292 416 852
2025/202615.360 751 924 1.075 857 1.249 3.559 1.978 2.029 1.902 556 219 261
2026/20272.571 235 596 686 904 150 0 0 0 0 0 0 0
Totale 37.029